These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Novel mutation (A141D) in exon 4 of the CFTR gene identified in an Algerian patient. Gouya L; Pascaud O; Munck A; Elion J; Denamur E Hum Mutat; 1997; 10(1):86-7. PubMed ID: 9222768 [No Abstract] [Full Text] [Related]
23. Sweat chloride concentration in cystic fibrosis patients with cystic fibrosis trans-membrane conductance regulator 11234V mutation. Al-Mendalawi MD; Abdul-Wahab A; Janahi IA; Abdel-Rahman MO Saudi Med J; 2010 Mar; 31(3):339-40; author reply 340. PubMed ID: 20231949 [No Abstract] [Full Text] [Related]
24. Exploring cystic fibrosis using bioinformatics tools: a module designed for the freshman biology course. Zhang X Biochem Mol Biol Educ; 2011; 39(1):17-20. PubMed ID: 21433248 [TBL] [Abstract][Full Text] [Related]
25. Introduction: molecular chaperones of the ER: their role in protein folding and genetic disease. Brooks DA Semin Cell Dev Biol; 1999 Oct; 10(5):441-2. PubMed ID: 10597626 [No Abstract] [Full Text] [Related]
26. Novel de novo large deletion in cystic fibrosis transmembrane conductance regulator gene results in a severe cystic fibrosis phenotype. Norek A; Stremska M; Sobczyńska-Tomaszewska A; Wertheim-Tysarowska K; Dmeńska H; Jurek M J Pediatr; 2011 Aug; 159(2):343-6.e1. PubMed ID: 21663921 [TBL] [Abstract][Full Text] [Related]
32. Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis. Hamilton JW Lancet; 2001 Dec; 358(9298):2014-6. PubMed ID: 11755605 [No Abstract] [Full Text] [Related]
33. New pharmaceutical approaches to the treatment of cystic fibrosis. Delaney SJ; Wainwright BJ Nat Med; 1996 Apr; 2(4):392-3. PubMed ID: 8597941 [No Abstract] [Full Text] [Related]
34. [Trends in the treatment of cystic fibrosis]. Rossi G Recenti Prog Med; 1999; 90(7-8):380-2. PubMed ID: 10429516 [No Abstract] [Full Text] [Related]
35. Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease. Amaral MD J Inherit Metab Dis; 2006; 29(2-3):477-87. PubMed ID: 16763920 [TBL] [Abstract][Full Text] [Related]
36. Targeting nonsense-mediated cystic fibrosis: is it premature to stop now? O'Sullivan BP Lancet Respir Med; 2014 Jul; 2(7):509-11. PubMed ID: 24836206 [No Abstract] [Full Text] [Related]
37. Ignoring the nonsense: a phase II trial in cystic fibrosis. Hyde SC; Gill DR Lancet; 2008 Aug; 372(9640):691-2. PubMed ID: 18722009 [No Abstract] [Full Text] [Related]
38. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Aslam A; Jahnke N; Remmington T; Southern KW Paediatr Respir Rev; 2017 Sep; 24():32-34. PubMed ID: 28566196 [No Abstract] [Full Text] [Related]
39. A breath of fresh air. Rowe SM; Clancy JP; Sorscher EJ Sci Am; 2011 Aug; 305(2):68-73. PubMed ID: 21827128 [No Abstract] [Full Text] [Related]
40. Antagonists to the rescue. Welch WJ; Howard M J Clin Invest; 2000 Apr; 105(7):853-4. PubMed ID: 10749562 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]